Harvest Global Investments Announces New CEO and Executive Appointments, Deepening Synergy with Parent Company Harvest Fund to Pioneer New Horizons in Cross-Border Investment

Harvest Global Investments Announces New CEO and Executive Appointments, Deepening Synergy with Parent Company Harvest Fund to Pioneer New Horizons in Cross-Border Investment

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Harvest Global Investments Limited ("HGI"), the international subsidiary of Harvest Fund Management, today announced a new round of executive leadership appointments. Mr. Charlie Chen, Managing Director of...

Autozi Internet Technology (Global) Ltd. Regains Nasdaq Compliance

Autozi Internet Technology (Global) Ltd. Regains Nasdaq Compliance

BEIJING, Jan. 14, 2026 /PRNewswire/ -- Autozi Internet Technology (Global) Ltd. ("Autozi" or the "Company") (Nasdaq: AZI), one of China's leading and fastest-growing lifecycle automotive service and supply-chain technology platforms, announced today...

Announcement from Trip.com Group

Announcement from Trip.com Group

SINGAPORE, Jan. 14, 2026 /PRNewswire/ -- Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) ("Trip.com Group" or the "Company"), a leading global one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours,...

Sino Land Achieves 'AAA' MSCI ESG Rating

Sino Land Achieves 'AAA' MSCI ESG Rating

ESG Strategies and Sustainable Practices Align with International Standards HONG KONG, Jan. 14, 2026 /PRNewswire/ -- Sino Group ('the Group') is pleased to announce that Sino Land Company Limited ('Sino Land') (Stock Code: 0083.HK) has received the...

APh ePower Secures 2025 R&D 100 Award for Pioneering Elevator Energy Recovery

APh ePower Secures 2025 R&D 100 Award for Pioneering Elevator Energy Recovery

The aluminum battery leader's Elevator Regenerative Power System reclaims wasted power and yields carbon credits with every lift. KAOHSIUNG, Jan. 13, 2026 /PRNewswire/ -- APh ePower, the global leader in commercialized aluminum battery technology,...

Sunwoda Joins 2026 Sungrow Global Partners Conference to Deepen Global Collaboration and Sustainability

Sunwoda Joins 2026 Sungrow Global Partners Conference to Deepen Global Collaboration and Sustainability

HEFEI, China, Jan. 8, 2026 /PRNewswire/ -- On January 8, Sunwoda, as a global partner of Sungrow, attended the 2026 Sungrow Global Partners Conference in Hefei, Anhui Province, to discuss international expansion and sustainable development. Wang...

Kolmar Korea Wins CES 2026 Best of Innovation Award in Beauty Tech, a Global First for the Cosmetics Industry

Kolmar Korea Wins CES 2026 Best of Innovation Award in Beauty Tech, a Global First for the Cosmetics Industry

Proving global competitiveness in beauty tech by capturing the CES "Best of Innovation Award" AI-powered 'Scar Beauty Device' earns double honors in Beauty Tech and Digital Health categories LAS VEGAS, Jan. 7, 2026 /PRNewswire/ -- Kolmar Korea...

Dreame Debuts Revolutionary Hair Care Lineup at CES 2026: AI-Powered Pilot 20 Hair Dryer Features Dual Robotic Arms for Proactive Care

Dreame Debuts Revolutionary Hair Care Lineup at CES 2026: AI-Powered Pilot 20 Hair Dryer Features Dual Robotic Arms for Proactive Care

LAS VEGAS, Jan. 7, 2026 /PRNewswire/ -- Dreame Technology, a global leader in high-end consumer electronics and intelligent manufacturing, today unveiled a series of smart beauty products redefining the future of personal care at CES 2026. The...

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and...

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

- The P hase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 16
  • menu
    menu